TianjinJune 15, 2026 /PRNewswire/ — During a visit to China, the global executive team of Novo Nordisk announced an additional investment of 200 million RMB in its strategic production base in Tianjin to enhance the assembly capacity of 1.5ml FlexTouch® injection pens. Once completed, the project will significantly boost the production capacity and supply efficiency of high-quality products, better meeting the growing and diverse medication needs of Chinese patients.
Novo Nordisk Tianjin Production Plant
As one of Novo Nordisk’s global strategic production bases, the Tianjin plant supplies injection devices and finished pharmaceutical products to China and other countries. The production and sustainable supply of the company’s products rely on advanced manufacturing processes, high-quality standards, and large-scale production capabilities. Novo Nordisk has decades of experience in highly specialized manufacturing, with production processes strictly adhering to the highest international regulatory standards and quality systems.
Kasper Bødker Mejlvang, Executive Vice President of Product Supply, Quality & IT at Novo Nordisk, stated: “As a key pillar of Novo Nordisk’s global supply chain, the Tianjin plant continues to support the localized production of innovative products. This investment further strengthens our manufacturing capabilities in China and reflects Novo Nordisk’s commitment to deepening its presence and long-term development in the country.”
Since entering China in 1994, Novo Nordisk has continuously expanded its footprint, now forming a strategic framework of “three engines” working in synergy: Beijing as the R&D engine, Tianjin as the production engine, and Shanghai as the commercial operations and innovation engine. Since 2003, Novo Nordisk has invested over 17 billion RMB in China cumulatively.